Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?

ABSTRACT:

Purpose

Ovarian cancer is the most lethal gynaecological malignancy. Despite the introduction of bevacizumab, standard chemotherapy has remained largely unchanged and the vast majority of patients will relapse within the first two years of diagnosis. However, results from recent clinical trials demonstrating clinical benefits of PARP inhibitor treatment are rapidly changing therapeutic options for many patients with ovarian cancer.

Methods

Given the introduction of new therapeutic options in the treatment of ovarian cancer, we critically review key clinical trials, areas of scientific research and its clinical relevance.

Results

Most notably, patients with BRCA1/2 mutant ovarian cancer benefit from maintenance treatment with PARP inhibitors after (complete or partial)

SUBMITTER: Klotz DM 

PROVIDER: S-EPMC7524817 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature